UNITY Biotechnology, Inc. to Announce First Quarter 2020 Financial Results

Rhea-AI Summary

UNITY Biotechnology (NASDAQ:UBX) plans to report its Q1 2020 financial results on May 7, 2020, after NASDAQ market close. No conference call will follow the announcement. The company focuses on developing therapeutics to extend healthspan by targeting cellular senescence, a key factor in aging and age-related diseases. UNITY aims to create senolytic medicines to eliminate senescent cells that contribute to chronic inflammation and other age-related health issues.

Positive

• No conference call indicates a streamlined approach to financial reporting.

Negative

• The absence of a conference call may limit investor engagement and transparency regarding financial results.

SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended March 31, 2020, on Thursday, May 7, 2020 after NASDAQ market close.

UNITY will not conduct a conference call in conjunction with the financial results press release.

About UNITY
UNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at its source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

Investors
Endurance Advisors
Peter Rahmer / Mike Zanoni
prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com

Media
Canale Communications
Jason Spark
jason@canalecomm.com

FAQ

When will UNITY Biotechnology report its Q1 2020 financial results?

UNITY Biotechnology will report its Q1 2020 financial results on May 7, 2020, after NASDAQ market close.

Will there be a conference call after the Q1 2020 financial results?

No, UNITY Biotechnology will not conduct a conference call in conjunction with the financial results press release.

What is the focus of UNITY Biotechnology's therapeutics?

UNITY Biotechnology is focused on developing therapeutics aimed at extending healthspan by targeting cellular senescence, which contributes to age-related diseases.

What is cellular senescence and why is it important for UNITY Biotechnology?

Cellular senescence is a biological state where cells stop dividing and accumulate with age, contributing to inflammation and age-related diseases; targeting this process is key to UNITY's therapeutic approach.